TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18258295

Group type: EXPERIMENTAL
Intervention: Resin cement (Compolute, 3M) with metal tribochemically treated (Group D)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Resin cement (Rely‐X Arc, 3M) with metal tribochemically treated (Group G)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Resin cement (Compolute, 3M) with no surface treatment (Group B)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Resin cement (Compolute, 3M) with dentin etched and bonded (Group C)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Resin cement (Rely‐X Arc, 3M) with no surface treatment (Group E)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Resin cement (Rely‐X Arc, 3M) with dentin etched and bonded (Group F)
Number of subjects: 105
Study: 16424071

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 12634979

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEXA) 2.0 mg i.v.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Prednisolone (PRED) 12.5 mg i.v.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline i.v. (Control)
Number of subjects: 8

Group type: COMPARATOR
Intervention: G-CSF s.c. alone
Number of subjects: 8
Study: 11201841

Group type: EXPERIMENTAL
Intervention: Policosanol (10 mg/day)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Besafibrate (400 mg/day)
Number of subjects: 113
Study: 9596865

Group type: EXPERIMENTAL
Intervention: Methyl carprost suppository (vaginal administration)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Methyl carprost suppository (rectal administration)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Oxytocin (intramuscular administration)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Oxytocin (intravenous administration)
Number of subjects: 360
Study: 8173194

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) given by continuous infusion (96 h) iv and ip, modulated by high-dose folinic acid-iv
Number of subjects: 13
Study: 3106248

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid
Number of subjects: 61

Group type: COMPARATOR
Intervention: Penicillin +/- dicloxacillin
Number of subjects: 61
Study: 29566026

Group type: EXPERIMENTAL
Intervention: Losmapimod 7.5mg twice daily for 16 weeks
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 27553419

Group type: EXPERIMENTAL
Intervention: M72/AS01E vaccine (n = 71)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo (n = 71)
Number of subjects: 142
Study: 25552432

Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 22911473

Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT (allo-HSCT)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Autologous HSCT (auto-HSCT)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 135

Group type: COMPARATOR
Intervention: NPM1+/FLT3-ITD- subgroup (allo-HSCT, auto-HSCT, chemotherapy)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: NPM1+/FLT3-ITD- patients
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: NPM1/FLT3-ITD other molecular profiles
Number of subjects: 135
Study: 20642343

Group type: EXPERIMENTAL
Intervention: Primary open-angle glaucoma (POAG)
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Intraocular pressure (IOP)
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Myopia
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Axial length
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Mean IOP
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Mean axial length
Number of subjects: 1244
Study: 18991473

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine extended release (CER) 30 mg once daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cyclobenzaprine immediate release (CIR) 10 mg three times daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both CER and CIR
Number of subjects: 18
Study: 18849294

Group type: EXPERIMENTAL
Intervention: Haloperidol and risperidone
Number of subjects: 491
Study: 16274373

Group type: EXPERIMENTAL
Intervention: Acetaminophen (3,000 mg/d)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 11862365

Group type: EXPERIMENTAL
Intervention: High-dose ascorbic acid (3 x 1000 mg/day Cetebe)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9445239

Group type: EXPERIMENTAL
Intervention: Extended cervical and superior mediastinal lymphadenectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional cervical and superior mediastinal lymphadenectomy
Number of subjects: 0
Study: 8033499

Group type: EXPERIMENTAL
Intervention: Nicotine skin patch plus oral mecamylamine (2.5 to 5 mg twice a day for 5 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nicotine skin patch plus placebo
Number of subjects: 48
Study: 2692022

Group type: EXPERIMENTAL
Intervention: Theophylline 390-900 mg daily (1/3 in the morning, 2/3 in the evening)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Terbutaline 15 mg daily (7.5 mg in the morning and 7.5 mg in the evening)
Number of subjects: 10
Study: 4301534

Group type: EXPERIMENTAL
Intervention: Synacthen (Ciba), injected either intramuscularly or intravenously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DW 75 (Sandoz), injected intravenously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DW 75 (Sandoz), injected intramuscularly
Number of subjects: 0
Study: 11524396

Group type: EXPERIMENTAL
Intervention: Atrial therapies 'on' (pacing and shock therapies)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Atrial therapies 'off' (no pacing and shock therapies)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Atrial pacing therapies only
Number of subjects: 52
Study: 29461283

Group type: EXPERIMENTAL
Intervention: Education about cervical cancer and human papillomavirus
Number of subjects: 156
Study: 30087456

Group type: EXPERIMENTAL
Intervention: Skin to skin care (SSC) provided at least 10 min before the procedure
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral Sucrose (0.2 ml) provided 2 min before the procedure
Number of subjects: 100
Study: 26705862

Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (spontaneous healing)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Other groups (preserved ridge)
Number of subjects: 60
Study: 24736085

Group type: EXPERIMENTAL
Intervention: 400 mg/day apricoxib plus 150 mg/day erlotinib (AP/E)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo plus 150 mg/day erlotinib (P/E)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 400 mg/day apricoxib plus 150 mg/day erlotinib (AP/E) in patients aged 65 years or younger
Number of subjects: 120
Study: 22332206

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 30
Study: 19274674

Group type: EXPERIMENTAL
Intervention: Communication skills training (CST)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (no CST)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Both groups (CST and Control)
Number of subjects: 113
Study: 17975233

Group type: EXPERIMENTAL
Intervention: GlideScope rigid stylet (GRS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard malleable stylet
Number of subjects: 80
Study: 15772061

Group type: EXPERIMENTAL
Intervention: Strenuous exercise
Number of subjects: 16
Study: 12425225

Group type: EXPERIMENTAL
Intervention: Stabilisation appliance (T-group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control appliance (C-group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mixed group (M-group)
Number of subjects: 60
Study: 10364634

Group type: EXPERIMENTAL
Intervention: 1 mM glucose solution
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10 mM glucose solution
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 100 mM glucose solution
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 67 mM glucose at 1.5 ml/min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 133 mM glucose at 0.75 ml/min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Antenatal glucocorticoids
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Higher infusion rate
Number of subjects: 16
Study: 7791383

Group type: EXPERIMENTAL
Intervention: Nimodipine (60 mg four times a day)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 95
Study: 1817934

Group type: EXPERIMENTAL
Intervention: AmF/SnF2 mouth rinse solution, rinsed 1x/d for 16 months
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 49
Study: 7006182

Group type: EXPERIMENTAL
Intervention: Atenolol, 50 mg, b.i.d.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Propranolol, 80 mg, b.i.d.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Atenolol and Propranolol (after excluding 7 patients with high headache days)
Number of subjects: 28
Study: 31881623

Group type: EXPERIMENTAL
Intervention: Decompressive surgery for migraine headaches
Number of subjects: 25

Group type: COMPARATOR
Intervention: Preoperative symptom profile
Number of subjects: 25

Group type: COMPARATOR
Intervention: Postoperative symptom profile
Number of subjects: 25
Study: 31149004

Group type: EXPERIMENTAL
Intervention: Propofol 100 µg/kg/min
Number of subjects: 87

Group type: COMPARATOR
Intervention: Ketofol (ketamine 25 µg/kg/min + propofol 75 µg/kg/min)
Number of subjects: 87
Study: 29123173

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 IU bolus followed by 4,000 IU daily cholecalciferol)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 26025336

Group type: COMPARATOR
Intervention: Pro12 genotype
Number of subjects: 138
Study: 24302008

Group type: COMPARATOR
Intervention: Control trial (absence of hyperglycemia)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hyperglycemia trial (5.4 mM above basal, plasma glucose increased to 11.2 ± 0.1 mmol/l)
Number of subjects: 10
Study: 22284287

Group type: EXPERIMENTAL
Intervention: Relaxin (50 μg weekly injections for 8 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (weekly injections for 8 weeks)
Number of subjects: 40
Study: 17882138

Group type: COMPARATOR
Intervention: Hydroxypropylmethylcellulose (HPMC) at 15 g day(‐1) for 1 week (medium, high, ultra-high viscosity)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Hydroxypropylmethylcellulose (HPMC) at 5 g day(‐1) for 8 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Hydroxypropylmethylcellulose (HPMC) at 15 g day(‐1) for 8 weeks
Number of subjects: 52
Study: 17890493

Group type: EXPERIMENTAL
Intervention: Exercise at 30% Vo(2max)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise at 50% Vo(2max)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phentolamine (alpha-AR antagonist) added to dialysis probe during exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phentolamine plus propranolol (beta-AR antagonist) during exercise at 30% and 50% Vo(2max)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise at 70% Vo(2max)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise-induced increase in plasma catecholamine levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma insulin levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide levels
Number of subjects: 0
Study: 15144295

Group type: EXPERIMENTAL
Intervention: 0.2 mg x kg(‐1) nefopam
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: 0.1 mg x kg(‐1) nefopam
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: 0.05 mg x kg(‐1) nefopam
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: 1.5 microg x kg(‐1) clonidine
Number of subjects: 371

Group type: COMPARATOR
Intervention: Saline 0.9% as placebo
Number of subjects: 371
Study: 11932287

Group type: EXPERIMENTAL
Intervention: Antiresorptive agents
Number of subjects: 2415
Study: 9691099

Group type: EXPERIMENTAL
Intervention: Isotretinoin treatment (80 mg/d; 5 d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retinoids in HepG2 cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LG1069 (RXR-specific agonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TTNPB (RAR-specific agonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RXR
Number of subjects: 0
Study: 8583465

Group type: COMPARATOR
Intervention: Intravenous captopril 1.25 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravenous captopril 12.5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravenous captopril 125 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral captopril 25 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2529815

Group type: EXPERIMENTAL
Intervention: Teicoplanin (3 to 7 mg/kg every 12 h on the first day, followed by 3 to 7 mg/kg every 24 h; or 8 to 14.4 mg/kg per day for some cases)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Teicoplanin alone
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Teicoplanin combined with one or more antibiotics
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Teicoplanin (7 to 14 mg/kg per day)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Teicoplanin in combination with aminoglycoside
Number of subjects: 23
Study: 360901

Group type: EXPERIMENTAL
Intervention: Ribavirin (300 mg/day, administered as capsules three times daily for 5 days)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (disguised)
Number of subjects: 45
Study: 30681017

Group type: EXPERIMENTAL
Intervention: SHP465 mixed amphetamine salts (25/50 mg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Immediate-release mixed amphetamine salts (12.5 mg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 28625750

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 292

Group type: COMPARATOR
Intervention: Age ≥75 years
Number of subjects: 292

Group type: COMPARATOR
Intervention: Postoperative pneumonia
Number of subjects: 292

Group type: COMPARATOR
Intervention: 6 or more packed red blood cell units transfusion in the first 24 hours postoperatively
Number of subjects: 292

Group type: COMPARATOR
Intervention: 24-hour postoperative albumin <3.0 g/dL
Number of subjects: 292
Study: 25813733

Group type: EXPERIMENTAL
Intervention: Intrapleural streptokinase instillation (IPSI)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Video-assisted thoracoscopic surgery (VATS)
Number of subjects: 35
Study: 24054898

Group type: EXPERIMENTAL
Intervention: Gradual training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sudden training
Number of subjects: 0
Study: 21872282

Group type: EXPERIMENTAL
Intervention: Normothermic CPB (35°C-37°C)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Hypothermic CPB (28°C)
Number of subjects: 59
Study: 19552810

Group type: EXPERIMENTAL
Intervention: Intervention (writing about one's own values)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Control (writing about another's values)
Number of subjects: 348
Study: 17997845

Group type: EXPERIMENTAL
Intervention: High protein, high fat (HPHF) meal
Number of subjects: 21

Group type: COMPARATOR
Intervention: High protein, low fat (HPLF) meal
Number of subjects: 21
Study: 15122768

Group type: EXPERIMENTAL
Intervention: Infliximab (10 mg/kg) with prednisolone (40 mg/day for 28 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo with prednisolone (40 mg/day for 28 days)
Number of subjects: 36
Study: 11496318

Group type: EXPERIMENTAL
Intervention: Oral regimen (doxifluridine + medroxyprogesterone acetate + cyclophosphamide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard regimen (5‐fluorouracil + adriamycin + cyclophosphamide + medroxyprogesterone acetate)
Number of subjects: 0
Study: 9792263

Group type: EXPERIMENTAL
Intervention: Chronic heart failure patients
Number of subjects: 13

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 13
Study: 7625110

Group type: EXPERIMENTAL
Intervention: 0‐1‐2‐12 month vaccination schedule
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Administration of vaccine at STD clinic (centre A)
Number of subjects: 331

Group type: COMPARATOR
Intervention: 0‐1‐6 month vaccination schedule
Number of subjects: 331

Group type: COMPARATOR
Intervention: Referred to vaccination centre (centre B)
Number of subjects: 331
Study: 2122710

Group type: EXPERIMENTAL
Intervention: Intravenous taurine (10 mg.kg‐1.d‐1)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (not receiving taurine)
Number of subjects: 34
Study: 211011

Group type: EXPERIMENTAL
Intervention: Buccal administration of 500 μg of fenoterol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhalation of 200 μg of fenoterol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhalation of 400 μg of fenoterol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30636725

Group type: EXPERIMENTAL
Intervention: Visual EMG biofeedback group (VSG)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination EMG‐controlled electrical stimulation with visual EMG biofeedback group (CBG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (CTG)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: EMG‐controlled electrical stimulation group (ESG)
Number of subjects: 36
Study: 27268381

Group type: EXPERIMENTAL
Intervention: Carbetocin (100 μg IV)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Syntometrine (5 IU oxytocin + 0.2 mg ergometrine)
Number of subjects: 300
Study: 26047975

Group type: EXPERIMENTAL
Intervention: 1 mg TA-8995
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: 2.5 mg TA-8995
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: 5 mg TA-8995
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: 10 mg TA-8995
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: 10 mg TA-8995 plus 20 mg atorvastatin
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: 10 mg TA-8995 plus 10 mg rosuvastatin
Number of subjects: 364
Study: 23702258

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21837785

Group type: EXPERIMENTAL
Intervention: Valacyclovir
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Famciclovir
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 19626540

Group type: EXPERIMENTAL
Intervention: CPA + IFN-alpha2
Number of subjects: 581

Group type: COMPARATOR
Intervention: CPA
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: IFN-alpha2 maintenance
Number of subjects: 581

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 581
Study: 17259483

Group type: EXPERIMENTAL
Intervention: Pramlintide
Number of subjects: 266

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study: 15227651

Group type: EXPERIMENTAL
Intervention: Vaginal digital assessment
Number of subjects: 89

Group type: COMPARATOR
Intervention: Dynamometric measurements
Number of subjects: 89
Study: 15514501

Group type: EXPERIMENTAL
Intervention: Trained (TR) group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LPS-stimulated cytokine production
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HI group (high TLR4 expression)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chronic resistance exercise training (2x wk for previous 24 months)
Number of subjects: 20
Study: 11020676

Group type: EXPERIMENTAL
Intervention: Independent practice plus periodic feedback
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Periodic feedback only
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control
Number of subjects: 84
Study: 9218639

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Jen-Chung point for 15 min
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 20
Study: 8355929

Group type: EXPERIMENTAL
Intervention: 1.5 mg recombinant human relaxin in 3% methylcellulose gel
Number of subjects: 40

Group type: COMPARATOR
Intervention: gel only (placebo)
Number of subjects: 40
Study: 3721942

Group type: EXPERIMENTAL
Intervention: Sulpiride (100 mg, oral and i.v. administration)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2675952

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitrazepam
Number of subjects: 0
Study: 30971241

Group type: EXPERIMENTAL
Intervention: Late PMDI (periarticular multimodal drug injection) administered before prosthetic implantation
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Early PMDI (periarticular multimodal drug injection) administered just after knee arthrotomy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Both early and late PMDI
Number of subjects: 48
Study: 27819756

Group type: EXPERIMENTAL
Intervention: Group A (GA) with prostatic calculi
Number of subjects: 212

Group type: COMPARATOR
Intervention: Group B (GB) without prostatic calculi
Number of subjects: 212
Study: 25872570

Group type: EXPERIMENTAL
Intervention: Nutritional supplement (arginine, glutamine, β-hydroxy β-methylbutyrate)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 24113595

Group type: EXPERIMENTAL
Intervention: Hand hygiene accountability program
Number of subjects: 109988

Group type: EXPERIMENTAL
Intervention: Hand hygiene adherence rates
Number of subjects: 109988
Study: 21896129

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid-based emollient foam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ceramide-containing emulsion cream
Number of subjects: 20
Study: 19894420

Group type: EXPERIMENTAL
Intervention: Experimental intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison intervention
Number of subjects: 0
Study: 17607014

Group type: EXPERIMENTAL
Intervention: CpG ODNs
Number of subjects: 0